Semaglutide vs Tirzepatide, Cagrilintide, and Retatrutide: Mechanisms & Research Insights Mazdutide (IBI362): The Next Generation Dual GLP 1 Glucagon Agonist for Obesity and Metabolic Health Mazdutide vs Survodutide Weight Loss Peptide Comparison Once weekly mazdutide, a glucagon like peptide 1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with obesity or overweight. Full GLORY 1 trial results: https: nej.md 4koUvaP Cagrilintide Combined with Semaglutide: A New Approach for Treatment of Obesity and Type 2 Diabetes ClinicSearch In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the